Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Christoph C, Geilen"'
Publikováno v:
Oncogene. 26:3364-3377
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted considerable attention as a novel anticancer agent. However, its efficiency may be diminished by occurring resistance in cancer cells. The mechanisms of TRAIL resistance in
Autor:
Georgi Tchernev, Bachtier M. Kurbanov, Lothar F. Fecker, Jürgen Eberle, Chalid Assaf, Constanze Schwarz, Uwe Trefzer, Christoph C. Geilen, Peter T. Daniel
Publikováno v:
Journal of Investigative Dermatology. 126:1366-1371
Prognosis of primary melanoma is presently based on morphological parameters, mainly tumor thickness. However, more reliable prognostic markers are needed that allow a better stratification of patients, especially with regard to therapeutic options.
A novel Bcl-x splice product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain
Publikováno v:
Oncogene. 25:2160-2169
Pro- and antiapoptotic proteins of the large Bcl-2 family are critical regulators of apoptosis via the mitochondrial pathway. Whereas antiapoptotic proteins of the family share all four Bcl-2 homology domains (BH1-BH4), proapoptotic members may lack
Autor:
Christoph C. Geilen, Lothar F. Fecker, Jürgen Eberle, Bahtier M. Kurbanov, Constantin E. Orfanos
Publikováno v:
Journal of Investigative Dermatology. 125:1010-1019
Therapy resistance is crucial for the high mortality of melanoma. The death ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) bears high potential as a new anticancer agent, as binding to the death receptors TRAIL receptor 1/deat
Autor:
Bernhard Gillissen, Lothar F. Fecker, Malte Oppermann, Christoph C. Geilen, Peter T. Daniel, Jürgen Eberle
Publikováno v:
Oncogene. 24:7369-7380
The proapoptotic BH3-only protein natural born killer / Bcl-2 interacting killer (Nbk/Bik) has been described to inhibit Bcl-2 and Bcl-xL, thereby supporting the death promoting ability of Bax. In order to evaluate its function in melanoma, we invest
Autor:
Meryem Bektas, Puneet S. Jolly, Jürgen Eberle, Christoph C. Geilen, Carola Müller, Sarah Spiegel
Publikováno v:
Oncogene. 24:178-187
While most of the pharmacological therapies for melanoma utilize the apoptotic machinery of the cells, the available therapeutic options are limited due to the ability of melanoma cells to resist programmed cell death. Human melanoma cell lines A-375
Autor:
Constantin E. Orfanos, Ulrich Schultz-Ehrenburg, C. Assaf, Matthias Steinhoff, Ethel Michele De Villiers, Christoph C. Geilen, Ivailo Petrov
Publikováno v:
Journal of Cutaneous Pathology. 31:199-204
Background: Verrucous carcinoma, a variant of squamous cell carcinoma, is distinct from squamous cell carcinoma in morphology and behavior. It preferentially occurs on the oropharyngeal mucosa, the urogenital mucosa, and the soles. In contrast to its
Autor:
Constantin E. Orfanos, Peter T. Daniel, Lothar F. Fecker, Thomas Wieder, Amir M. Hossini, Christoph C. Geilen, Jürgen Eberle
Publikováno v:
Oncogene. 22:9131-9141
The significance of CD95/Fas ligand expression by melanoma cells has remained a controversial matter in recent years. On the other hand, CD95 activation may represent a powerful tool for eliminating tumor cells. Here, we demonstrate expression of CD9
Publikováno v:
Melanoma Research. 13:555-562
Phospholipase D (PLD) is a highly regulated enzyme involved in lipid-mediated signal transduction processes affecting vesicular trafficking and cytoskeletal reorganization. It is regulated by protein kinase C, adenosine diphosphate (ADP)-ribosylation
Autor:
Sergij Goerdt, Constantin E. Orfanos, M Koenigsmann, Eckhard Thiel, Claus-Detlev Klemke, Christoph C. Geilen, Edgar Dippel
Publikováno v:
Journal of the American Academy of Dermatology. 49:233-236
Histiocytoses are diseases caused by proliferation of either dendritic cells/Langerhans cells or of monocytes/macrophages. Generalized eruptive histiocytosis belongs to the cutaneous non-Langerhans cell histiocytoses and is a rare monocyte-macrophage